Literature DB >> 19995940

Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms.

Susana Mato1, Rebeca Vidal, Elena Castro, Alvaro Díaz, Angel Pazos, Elsa M Valdizán.   

Abstract

Increasing data indicate that brain endocannabinoid system plays a role in the effects of antidepressant medications. Here we examined the effect of in vivo exposure to the selective serotonin uptake inhibitor fluoxetine on cannabinoid type 1 (CB(1)) receptor density and functionality in the rat prefrontal cortex (PFC) and cerebellum. Long-term treatment with fluoxetine (10 mg/kg/day) enhanced CB(1) receptor inhibition of adenylyl cyclase (AC) in the PFC and reduced it in the cerebellum without altering receptor density and agonist stimulation of guanosine 5'-O-(3-[(35)S]thio) triphosphate ([(35)S]GTP gamma S) in either area. Analysis of [(35)S]GTP gamma S-labeled G alpha subunits allowed for the detection of up-regulated CB(1) receptor coupling to G alpha(i2), G alpha(i3) in the PFC, and reduced coupling to G alpha(i3) in the cerebellum of fluoxetine-treated rats. Concomitant administration of the 5-HT(1A) receptor antagonist N-[2-[4- (2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY100635; 0.1 mg/kg/day) reduced fluoxetine-induced modulation of CB(1) receptor coupling to G alpha subunits and AC in the PFC but not in the cerebellum. These results indicate that increased CB(1) receptor signaling at the G alpha(i)-AC transduction level is a long-term adaptation induced by fluoxetine in the PFC and point to a role for 5-HT(1A) receptors in this effect. Basal AC activity, protein kinase A (PKA) catalytic subunit expression, and phospho-cAMP response element-binding protein (pCREB)/CREB ratio were also up-regulated in the PFC of fluoxetine-treated animals, whereas no differences were detected in the cerebellum. It is interesting that long-term Delta(9)-tetrahydrocannabinol treatment did not elicit antidepressant-like effects or modulated behavioral responses of fluoxetine in an animal model of depression (olfactory bulbectomy). These data suggest that altered signal transduction through CB(1) receptors in the PFC may participate in the regulation of the AC-PKA-CREB cascade induced by fluoxetine in this brain area.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995940     DOI: 10.1124/mol.109.060079

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  α₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims.

Authors:  Elsa M Valdizán; Rebeca Díez-Alarcia; Javier González-Maeso; Fuencisla Pilar-Cuéllar; Jesús A García-Sevilla; J Javier Meana; Angel Pazos
Journal:  Biol Psychiatry       Date:  2010-09-22       Impact factor: 13.382

2.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

3.  Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders.

Authors:  Susana Mato; Fuencisla Pilar-Cuéllar; Elsa M Valdizán; Javier González-Maeso; Rafael Rodríguez-Puertas; Javier Meana; Joan Sallés; Benedicto Crespo-Facorro; Ángel Pazos
Journal:  Biochem Pharmacol       Date:  2018-08-10       Impact factor: 5.858

4.  Vilazodone for cannabis dependence: A randomized, controlled pilot trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese Killeen; Karen J Hartwell; Susan J Simonian
Journal:  Am J Addict       Date:  2015-12-20

5.  The relationship between single nucleotide polymorphisms in 5-HT2A signal transduction-related genes and the response efficacy to selective serotonin reuptake inhibitor treatments in Chinese patients with major depressive disorder.

Authors:  Heng-Fen Li; Xue Yu; Kun Yang; Cha-Ye He; Shao-Jie Kou; Su-Xia Cao; Guang-Rong Xie
Journal:  Genet Test Mol Biomarkers       Date:  2012-04-05

6.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

7.  Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.

Authors:  Georgina Valeria Fernández Macedo; María Laura Cladouchos; Laura Sifonios; Pablo Martín Cassanelli; Silvia Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2012-09-08       Impact factor: 4.530

8.  The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress.

Authors:  Maya First; Irit Gil-Ad; Michal Taler; Igor Tarasenko; Nurit Novak; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2012-09-12       Impact factor: 3.444

9.  Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.

Authors:  Alline Cristina Campos; Vanessa de Paula Soares; Milene C Carvalho; Frederico Rogerio Ferreira; Maria Adrielle Vicente; Marcus Lira Brandão; Antonio Waldo Zuardi; Hélio Zangrossi; Francisco Silveira Guimarães
Journal:  Psychopharmacology (Berl)       Date:  2012-09-25       Impact factor: 4.530

10.  Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.

Authors:  Estefanía Moreno; Clara Andradas; Mireia Medrano; María M Caffarel; Eduardo Pérez-Gómez; Sandra Blasco-Benito; María Gómez-Cañas; M Ruth Pazos; Andrew J Irving; Carme Lluís; Enric I Canela; Javier Fernández-Ruiz; Manuel Guzmán; Peter J McCormick; Cristina Sánchez
Journal:  J Biol Chem       Date:  2014-06-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.